Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04042376 · OUTCOME

Clinical Response Rate (CRR)

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) · Source last updated 2025-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
90% Confidence Interval
Time frame
From start of the treatment (Day 1) up to 49.3 months

What was measured

CRR was defined as the percentage of participants who achieved minor response (MR) or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. MR: \>=25% but less than (\<) 50% reduction of serum IgM from baseline.

Analysis population: All treated analysis set included all enrolled participants who received at least 1 dose of study drug.

Groups in this outcome

Ibrutinib 420 mg

Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ibrutinib 420 mg17

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Ibrutinib 420 mg100.0Not reported83.8100.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        83.8
        upper Limit
        100.0
        value
        100.0
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
CRR was defined as the percentage of participants who achieved minor response (MR) or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. MR: \>=25% but less than (\<) 50% reduction of serum IgM from baseline.
dispersion Type
90% Confidence Interval
groups
  1. description
    Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.
    id
    OG000
    title
    Ibrutinib 420 mg
param Type
NUMBER
population Description
All treated analysis set included all enrolled participants who received at least 1 dose of study drug.
reporting Status
POSTED
time Frame
From start of the treatment (Day 1) up to 49.3 months
title
Clinical Response Rate (CRR)
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice